医疗保险住院患者胸腺五肽注射剂应用分析  

Analysis of the Application of Thymopentin Injections in Inpatients with Medical Insurance

作　　者：康洽福[1] 周灵[1] 商姗 

机构地区：[1]福建省医疗保险管理中心铁路分中心,福州350013 [2]中国人民健康保险股份有限公司福建分公司,福州350001

出　　处：《中国药房》2012年第6期517-519,共3页China Pharmacy

摘　　要：目的:评价福建省医疗保险管理中心铁路分中心(简称"我中心")二级以上定点医院胸腺五肽(TP-5)注射剂的应用情况。方法:调取我中心24家定点医院2010年1-6月应用TP-5注射剂的339份住院患者病历,根据医疗待遇、出院诊断分别统计费用、住院时间、现金支付比例等数据以及联合应用免疫增强剂的情况。结果:住院时间、现金支付比例、患者年龄等因素均能影响TP-5注射剂的临床应用;29.77%的患者无用药指征;52.51%的病例联用1种及以上免疫增强剂。结论:我中心定点医院TP-5注射剂临床应用存在不合理现象;联合应用免疫增强剂可能存在过度医疗行为;各级监管部门应制定有针对性的措施以遏制医疗费用过快增长。OBJECTIVE： To evaluate the application of Thymopentin （TP-5） injections in grade II - III general hospitals of Railway Branch of Fujian Province Medical Insurance Management Center （called ＂our center＂ in short）. METHODS： Medical records of 339 inpatients who used TP-5 injection from Jan. 2010 to Jun. 2010 were collected from 24 hospitals of our center. According to insured medical treatment and discharge diagnosis, the cost, hospitalization days, cash-payment ratio, the combined use of immunopotentiator were analyzed statistically. RESULTS： The application of TP-5 injection was affected by some factors such as hospitalization day, cash-payment ratio and age of patients, etc. About 29.77% of patients were without the use of the drug indica- tions; about 52.51% of patients used more than one kind of immunopotentiator. CONCLUSION： The uses of TP-5 injections are ir- rational in hospitals of our center. Combined use of immunopotentiator is excessive. Medical supervision department ought to make some focal methods to restrain the upward of medical expense.

关 键 词：胸腺五肽注射剂 免疫增强剂 医疗保险 医疗监管 

分 类 号：R969.3[医药卫生—药理学] R952[医药卫生—药学]